Ming-chih Liu

1Division Of Hematology, No.7, Chung Shan S. Rd
Zhongzheng Dist, TPQ 10002, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification.

Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification.

Journal: Blood cancer journal

Published: September 09, 2025

Prognostic impact of lymphocyte to monocyte ratio in patients with myelodysplastic neoplasms/syndromes.

Prognostic impact of lymphocyte to monocyte ratio in patients with myelodysplastic neoplasms/syndromes.

Journal: Blood research

Published: September 03, 2025

Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World Analysis.

Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World Analysis.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 06, 2025

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations.

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations.

Journal: Blood cancer journal

Published: February 13, 2025

Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends.

Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends.

Journal: Clinical lymphoma, myeloma & leukemia

Published: November 25, 2024

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.

Journal: Blood cancer journal

Published: December 23, 2023

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.

Journal: Blood cancer journal

Published: December 23, 2023

Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations.

Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations.

Journal: Blood cancer journal

Published: April 04, 2023

Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.

Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.

Journal: Blood cancer journal

Published: March 16, 2023

Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.

Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.

Journal: Blood cancer journal

Published: March 16, 2023

Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML.

Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML.

Journal: Blood cancer journal

Published: December 07, 2022

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.

Journal: American journal of hematology

Published: November 14, 2022

Showing 1-12 of 40

Last Updated: 09/26/2026